Academic History
Frederick Locke, MD, is a Medical Oncologist and Translational Researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, Tampa, FL.
After obtaining a medical degree from Wayne State University, Detroit, MI, Dr Locke underwent a Residency in Internal Medicine at Wayne State University/Detroit Medical Center, followed by a Fellowship in Hematology/Oncology at University of Chicago Medical Center, Chicago, IL.
Dr Locke is a leading clinical researcher in CAR-T cell therapy, serving as a national principal investigator for key anti-CD19 CAR-T trials in lymphoma. His research also focuses on developing new cellular immunotherapies, including a Moffitt-created survivin tumor vaccine for multiple myeloma.
Speaking on CAR-T therapies for B-cell malignancies
Dr Locke speaks on the CAR-T therapies for B-cell malignancies, with a particular focus on large B-cell lymphoma (LBCL). He discusses the ZUMA trials which investigate axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) in B-cell malignancies.
